公司資料
Entera Bio 股價、新聞與催化劑
- 股票代碼:
- ENTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Israel and listed in the U
股票表現
2.90 USD (+0.35%)
收盤價
最後更新: 2026年8月17日
61.5M USD
市值
股價為何變動
The latest monitored company update is “Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation.” The corresponding closing-price reaction is not yet available.
公司概覽
Oral Peptide Delivery
Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection. Its proprietary N-Tab platform is designed to improve intestinal absorption in a convenient tablet form.
EB613 Osteoporosis Program
EB613 is an oral parathyroid-hormone peptide candidate intended to provide anabolic, bone-building treatment for postmenopausal osteoporosis without daily injections.
EB612 Hypoparathyroidism Program
EB612 is an oral long-acting PTH replacement candidate for hypoparathyroidism. It is being developed through an equal partnership with OPKO Health.
EB618 Metabolic Program
EB618 is an oral oxyntomodulin candidate designed for dual GLP-1 and glucagon receptor activity in metabolic and fibrotic diseases, extending the platform beyond replacement therapies.
Platform Business Model
Entera uses N-Tab both for internally controlled candidates and partnered programs, allowing the same delivery technology to support multiple peptide classes and therapeutic areas.
未來催化劑
- FDA feedback on the submitted Phase 3 protocol for EB613.
- IND submission for EB612 in late 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。